Overview

Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
0
Participant gender:
Female
Summary
To explore the antiviral effect of nucleoside analogue in late pregnancy and the safety of the antiviral drug to fetus.To establish the best therapy strategy to pregnant women with high level of HBV DNA.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hua Zhang
Collaborator:
Icahn School of Medicine at Mount Sinai
Treatments:
Lamivudine
Telbivudine
Criteria
Inclusion Criteria:

HBeAg+CHB pregnant woman gestational age 28 weeks HBV-DNA>log10 copies/ml

Exclusion Criteria:

co-infection with hepatitis A,C,D,E or HIV evidence of hepatocellular carcinoma
decompensated liver disease or significant co-morbidity concurrent treatment with
immune-modulators,cytotoxic drugs,or steroids clinical signs of threatened miscarriage in
early prenancy evidence of fetal deformity by ultrasound examination the biological father
of the child had CHB